Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Learn what tax lots are in automated investing, why they matter for cost basis and tax reporting, and how to use them to optimize your portfolios.
14,599 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Boeing’s stock is drawing fresh attention as defense-focused equities outperform, underpinned by a robust backlog and...
A top institutional trader doubled down on PTCT, adding thousands of shares in a high-conviction move. This analysis ...
A practical guide to understanding Fuel Tech (FTEK) in 2025. Learn what to watch in Q4 results, identify catalysts, a...
Rocket Lab and AST SpaceMobile sit on opposite ends of the space-investing spectrum. This guide breaks down what each...
As Samsara charts its path in the IoT space, the focus turns to 2026 earnings and what they signal for growth, profit...
Is AMD headed for $300 a share? This deep-dive explains the hurdles, opportunities, and a practical game plan for 202...
When the PC market slows, smart investors look beyond laptops. A new wave of winners emerges—from memory makers to AI...
Could Zcash flip Bitcoin? This article breaks down how Zcash’s privacy features, regulatory dynamics, and market tren...
In the fast-moving world of micro-scale tech, rapid micro (rpid) earnings calls can signal whether a company is susta...
Tesla faced a rocky period, but a few hopeful indicators suggest the EV leader may be on a steadier path. This articl...
As geopolitical tensions rise, investors reassess defense exposure. This report examines the weapons that changed war...